Osmotica to Present at 10th Annual SVB Leerink Global Healthcare Conference
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) announced that CEO Brian Markison and CFO Andrew Einhorn will present at the 10th Annual SVB Leerink Global Healthcare Conference on February 24, 2021, at 9:20 a.m. Eastern Time.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) announced that CEO Brian Markison and CFO Andrew Einhorn will present at the 10th Annual SVB Leerink Global Healthcare Conference on February 24, 2021, at 9:20 a.m. Eastern Time. The presentation will be accessible via webcast at this link. Osmotica is a biopharmaceutical company focusing on specialty products for underserved markets, with operations in the U.S., Argentina, and Hungary.
Details
News Market Reaction – OSMT
The recorded move for OSMT in the trading session of this news was -0.46%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRIDGEWATER, N.J., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, and Andrew Einhorn, Chief Financial Officer, will present at the 10th Annual SVB Leerink Global Healthcare Conference as follows:
| Date: | Wednesday, February 24, 2021 |
| Time: | 9:20 a.m. Eastern Time |
| Webcast: | https://wsw.com/webcast/svbleerink47/osmt/2693120 |
About Osmotica Pharmaceuticals plc
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations. The company has a diverse portfolio consisting of promoted and non-promoted products, several of which incorporate Osmotica’s proprietary Osmodex® drug delivery system. RVL Pharmaceuticals, Inc. is the Company’s ophthalmic subsidiary supporting Upneeq. Vertical Pharmaceuticals, LLC represents the Company’s diversified branded portfolio and Trigen Laboratories, LLC represents the Company’s non-promoted products, including complex generic formulations. Osmotica has operations in the United States, Argentina, and Hungary.
Investor and Media Relations for Osmotica Pharmaceuticals plc
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.